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Growing evidence suggests that gene-regulatory networks, which are responsible for directing cardiovascular development,
are altered under stress conditions in the adult heart. The cardiac gene regulatory network is controlled by cardioenriched
transcription factors and multiple-cell-signaling inputs. Transcriptional coactivators also participate in gene-regulatory circuits as
the primary targets of both physiological and pathological signals. Here, we focus on the recently discoveredmyocardin-(MYOCD)
related family of transcriptional cofactors (MRTF-A and MRTF-B) which associate with the serum response transcription factor
and activate the expression of a variety of target genes involved in cardiac growth and adaptation to stress via overlapping but
distinct mechanisms. We discuss the involvement of MYOCD, MRTF-A, and MRTF-B in the development of cardiac dysfunction
and to what extent modulation of the expression of these factors in vivo can correlate with cardiac disease outcomes. A close
examination of the findings identifies the MYOCD-related transcriptional cofactors as putative therapeutic targets to improve
cardiac function in heart failure conditions through distinct context-dependent mechanisms. Nevertheless, we are in support of
further research to better understand the precise role of individual MYOCD-related factors in cardiac function and disease, before
any therapeutic intervention is to be entertained in preclinical trials.
1. Introduction
Heart failure (HF) is the common end-stage condition of
various cardiovascular disorders characterized by a progres-
sive decrease in cardiac output combined with insuﬃcient
or absent compensatory mechanisms. HF is a major public
health problem aﬀecting 15 million patients in the European
Union [1]. In descriptive terms, HF can be classified as
acute or chronic, congestive, systolic or diastolic, with high
or low output, left sided or right sided, and backward
or forward. Prevalent causes of sporadic (nonfamilial) HF
include myocardial infarction, hypertension, and ischemic
or dilated cardiomyopathy. Diuretics, ACE (angiotensin-
converting enzyme) inhibitors, and angiotensin-II receptor
blockers improve survival in patients with chronic HF but
do not prevent cardiomyocyte molecular and structural
deterioration (reviewed in [2]). Despite progress in both
clinical investigation and basic cardiovascular research (see
[3–5]), targeting the molecular mechanisms that promote
and sustain HF development in patients still remains elusive
(albeit with certain progress, see [6, 7]).
Extensive research over the past 10 years has begun to
provide significant advances in our understanding of the
interplay between heart development and disease [8–11].
The important step in this direction is illustrated by recent
studies of gene regulatory networks (GRNs) operating in
cardiac muscle cells [12–15]. The unraveling of GRNs in
both normal and diseased heart oﬀers the opportunity
to identify single key factors for regulation of the gene
expression networks which are ubiquitously altered in failing
myocardium, regardless of the etiology of HF [16].
The major players involved in cardiac GRNs are tran-
scription factors, notable among which is the serum response
factor (SRF; [15]). SRF, a member of the MADS (MCM1,
AG, DEFA, SRF) box family of transcription factors, binds
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as a dimer to specific sites (known as CArG boxes located
within serum response elements) on DNA driving the
expression of hundreds of target genes in a wide array of
cell types and tissues, from brain to cardiac muscle [17–19].
Although ubiquitously expressed, SRF plays specialized roles
in diﬀerent cellular environments. One of themechanisms by
which SRF regulates gene expression in a cell-specificmanner
is through SRF recruitment of several cofactors which
are specifically expressed in a given cell type. In diﬀerent
muscle cell types (cardiac, smooth, skeletal), cell-specific
regulation of the SRF-dependent gene expression is achieved
by SRF binding of specific coactivators, such as myocardin
(MYOCD) and myocardin-related transcription (MRTF)
cofactors, MRTFA and MRTFB (reviewed in [20–23]).
The data from both animal models and clinical research
in patients provided evidence of pathological consequences
of both SRF redundancy and deficiency in the adult heart. In
fact, SRF hyperexpression can lead to pathological hypertro-
phy, while inhibition of SRF activity can result in develop-
ment of dilated cardiomyopathy (reviewed in [18]). In light
of the involvement of SRF in adverse cardiac remodeling, it
has been of interest to explore the potential contributions
of MYOCD family members, as SRF coactivators, to heart
disease. As a result, the data accumulated over the last
years clearly implicate the MYOCD protein family in several
common forms of adult cardiac disease, such as pathological
cardiac hypertrophy, myocardial infarction, and HF [24].
Moreover, the MYOCD gene expression is upregulated in
circulating blood cells of patients with sporadic hypertrophic
cardiomyopathy [25] or hypertension [26].
There have been a series of excellent reviews onmolecular
and functional characterization, and regulation of MYOCD
and MRTFs in diﬀerent muscle and nonmuscle cell types
[20, 24, 27–29], and these essential facets will be commented
relatively briefly here. Instead, this paper emphasizes recent
insights into the involvement of transcriptional cofactors of
theMYOCD family in cardiac dysfunction and to what extent
experimental modulation of these factors’ expression in vivo
can correlate with cardiac disease outcome.
2. Myocardin Family Proteins:
Functional Domains and Transcription
Factor Binding Motifs
Themyocardin protein family includes (asmentioned above)
MYOCD itself and two MYOCD-related transcription fac-
tors, MRTF A and B (also referred to as MAL/MKL1 and
MAL16/MKL2, resp.). Properties of the MYOCD-related
family of SRF-binding cofactors have been characterized
most extensively in MYOCD itself, as the founding member,
and are presumed to be shared among other MYOCD family
members. Although sometimes members of the MYOCD
protein family are called “transcription factors” (see, e.g.,
[24]), they do not bind to DNA itself. Instead, they form
a ternary complex with SRF anchored to the CArG box of
promoters of cardiac and smooth muscle (SM) contractile
genes.
MYOCD is a SAP (scaﬀold-attachment factor A/B,
Acinus, PIAS) domain protein that was discovered by Olson’s
group during an in silico search for genes underlying early
heart development [30]. Mrtf-A and Mrtf-B were initially
isolated by Wang and colleagues [31] on screening cDNA
libraries with Myocd-related probes. All of them show a
similar domain organization (Figure 1) consisting of RPEL
motifs, a basic domain, a glutamine-rich region, a SAP
domain, a leucine zipper-like region, and a transcription
activation domain.
The N-terminal region of MYOCD proteins contains
several RPEL motifs (known also as RPEL domain) capable
of interacting with globular actin. Diﬀerences between
RPEL domains appear to define diﬀerent nucleocytoplasmic
transport activities of MYOCD family proteins: MYOCD
is constitutively located in the nucleus whereas its family
members, MRTF-A and MRTF-B, mostly reside in the
cytoplasm and translocate to the nucleus in response to actin
polymerization (formore details see [37, 38]). Recently, it has
been shown that nuclear accumulation of MYOCD family
members also depends on their diﬀerent relative aﬃnities for
nuclear import factors [39, 40]. Of note, the MEF2 (myocyte
enhancer factor 2) binding motif located in RPEL1 is unique
to MYOCD; transfer of this MEF2 binding motif to MRTF-
A confers the ability to co-activate the MEF2 transcription
factor [32]. The other SAP domain protein (namedMASTR)
shares this motif with MYOCD and acts as a MEF2 co-
activator [41].
MRTF-A and MRTF-B share strong sequence homology
with MYOCD in the basic and Q-rich domains, which
are responsible for SRF binding. The SAP domain, char-
acteristically observed in diverse nuclear proteins involved
in chromatin organization/remodeling, is not required for
interaction of MYOCD proteins with SRF. However, muta-
tions in the SAP domain ofMYOCD aﬀect activation of some
SRF-dependent gene targets, but not others, suggesting a role
of this domain in target gene discrimination. Although all
MYOCD proteins have a highly conserved transactivation
domain at their C-terminal region, MRTF-A activates CArG-
dependent SM-gene promoters reaching levels similar to
those induced by MYOCD itself, whereas MRTF-B is less
eﬀective in this regard. Several consensus regions of MYOCD
have been shown to be putative sites for binding of tran-
scription factors, other than SRF, which are also involved in
regulation of cardiac gene transcription and expression or
associated with the response of cardiac tissue to stress (see
Figure 1, MEF-2, TBX5, GATA4, and NKX3.1). Forthcoming
studies should reveal the full potential of the MYOCD family
in cardiac transcription regulatory networks.
Formally viewed, a high degree of domain similarity
between members of the MYOCD family indicated they
could have similar or overlapping functions in developing
and adult heart. However, evidence of similar domain
organization alone does not prove that MYOCD family
members do in fact perform identical or similar functions or
actions in the heart. Basic assumptions regarding similarities
and diﬀerences in their expression and functions in cardiac
tissue are discussed next.
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Figure 1: The myocardin family of transcriptional cofactors: protein signatures, domains, and functional sites. The domain/motif structures
of the human proteins are shown: RPEL 1-3 (RPEL domain), B: basic domain, Q: glutamine-rich region, SAP: SAP domain; S: serine-rich
region; CC: coiled-coil (leucine zipper-like) motif; P: proline-rich region; TAD: transcription activation domain. The regions essential for
binding of transcription factors (TF). MEF2: myocyte enhancer factor-2 [32], TBX5: T-box transcription factor 5 [33], FOXO4: forkhead
box protein O4 [34], GATA-4: member of GATA family of zinc finger transcription factors [35], NKX-3.1: homeobox NK-3 transcription
factor-1 [36]. NT/CT: amino/carboxyl terminus.
3. Myocardin Family Proteins and
Heart Development: Lessons from
Mouse Knockout Models
Complete loss-of-function (total/global or constitutive gene
knockout) experiments suggest the function(s) of a gene
of interest through the phenotype that results from its
deficiency in mouse mutants and, by extrapolation, in
humans. Even an early embryonic lethal phenotype might
be informative enough to predict a gene as essential for a
given fetal tissue/organ, but roles the gene may play later
in development as well as in postnatal/adult life remain
unknown. To overcome these problems, techniques have
been developed to create conditional knockout models, in
which a gene of interest can be inactivated in a spatially
and temporally controlled fashion. Several such approaches
have been used to evaluate to which extent the members
of the MYOCD family of transcriptional cofactors are
involved inmolecular and cellular processes underlying heart
development and maturation.
The members of the MYOCD family are coexpressed
in cardiac as well as diﬀerent SM lineages during early
mouse embryonic development [30, 31]. Although a
single gene-null mutation in Myocd and Mrtf-B resulted
in a wide range of tissue abnormalities and embryonic
lethality, here we will consider only structural and functional
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consequences of inactivation of these genes in the heart and
associated structures. (For accounts of the wider spectrum
of perturbations observed in these knockouts, see references
provided in Table 1).
In mice, the complete loss ofMyocd leads to a severe early
developmental, lethal phenotype from a failure in vascular
SM diﬀerentiation [42]. However, early cardiogenesis was
unaﬀected in the Myocd-null mice. Heart development in
Myocd knockouts could be partially rescued by redundant
activities of Mrtf-A and/or Mrtf-B. Although repeatedly
stated, this suggestion has not yet been tested experimentally.
By contrast, despite the fact that both Myocd and Mrtf-B
are coexpressed in embryonic vascular SM cells, Myocd-null
mice lack diﬀerentiated SM cells in the dorsal aorta and
placental vasculature.
Due to the early lethal phenotype of the Myocd-null
embryos, a conditional knockout approach was taken for
selective ablation of Myocd in developing heart. Cardio-
restricted inactivation of the Myocd gene did not alter
heart development. However, after birth mutant mice with
a conditionally inactivated Myocd gene develop dilated
cardiomyopathy (DCM) accompanied by impaired car-
diomyocyte structural organization and severely depressed
systolic function [43]. In chimeric Myocd knockout mice,
generated by injection of Myocd-null embryonic stem cells
into wide-type blastocysts,Myocd-null cells fail to contribute
to formation of ventricular myocardium, although these cells
were phenotypically normal and did not display ultrastruc-
tural alterations [50]. Moreover, these results imply that
Myocd is absolutely required for functional development of
ventricular myocardium and can play a pivotal role in the
response of the heart to stressful stimuli after birth.
In contrast to Myocd-null embryos, Mrtf-B homozygous
null or hypomorphic knockout embryos express cardiovas-
cular phenotypic abnormalities resembling those observed
in human patients with congenital heart disease. Although
knockout models used in these studies resulted in phenotype
of diﬀering severity, thin-walled ventricular myocardium
and ventricular septal defects were observed in each model
setting. Abnormal patterning of the branchial arch arteries
[47] and truncus arteriosus [48, 49] are also among the
other common manifestations (see Table 1). Although the
consequences of depleting Mrtf-B specifically within the
myocardium have not yet been reported, the results of
globalMrtf-B knockouts demonstrate that this factor is abso-
lutely required for embryonic heart development, specifically
within ventricular and cardiac outflow tract compartments.
The role of Mrtf-A in cardiovascular development is still
unclear. Two groups have independently shown that Mrtf-
A knockouts are viable and can reach adulthood without
obvious cardiac or other organ abnormalities; only knockout
females possess mammary gland dysfunction due to the
failure of mammary myoepithelial cells to diﬀerentiate [44,
46]. Although Mrtf-A is not absolutely required for heart
development, it may play a particular role in the survival
of myocardial cells during certain periods of development:
a set of Mrtf-A null mouse embryos suﬀered dilatation
of all cardiac chambers and died at midgestation stages
[46]. In addition, young adult mice lacking Mrtf-A show
a significantly weaker hypertrophic response to both acute
and chronic pressure overload suggesting Mrtf-A is involved
in hypertrophy signaling pathways in the postnatal heart
[45, 51].
Mice lacking each member of the Myocd family exhibit
distinct global phenotypes during development [24, 28].
Within the cardiovascular system, knockout mutations in
the Myocd, Mrtf-A, or Mrtf-B gene specifically aﬀect distinct
aspects of heart formation at diﬀerent stages of development.
Inactivation of Mrtf-B drastically alters pattern formation
in the developing heart that can lead to congenital heart
malformations, whereas deficiency in Myocd and Mrtf-A
becomes phenotypically evident in rather mature heart
resulting, respectively, in development of severe DCM or
poor hypertrophic response. Whether these factors are also
involved in adult heart function and, if so, how these factors
modulate the responsiveness of the heart to stress signaling is
highlighted below.
4. Myocardin Family Proteins in Adult Heart
Once heart development is completed, postnatal functional
maturation of the heart takes over extending the use of
cardiac GRNs to adulthood raising the possibility that some
forms of adult heart disease can result from adult-related
alterations in components of these regulatory pathways [52–
55].
Members of MYOCD gene family are expressed in
normal and diseased adult myocardium. The ventricular
myocardium, a highly ordered tissue structure, consists
of diﬀerent cell types (cardiac myocytes, fibroblasts, and
vascular endothelial and SM cells) which all are involved
in myocardial remodeling in response to physiological and
pathological stresses. Here, we will discuss arguments which
suggest the possible functions of MYOCD family factors
in both cardiomyocyte and fibroblast cell compartments of
adult myocardium (Figure 2).
4.1. MYOCD. MYOCD is absolutely required for mainte-
nance of adult heart function. Cardio-restricted inactivation
of the Myocd gene in the adult mouse heart resulted in
development of severe four-chambered DCM as a result of
massive myocyte loss via apoptosis and replacement fibrosis.
Mrtf-B, showing nonaltered cardiac expression, did not
rescue the DCM phenotype in Myocd-knockdown mice. It
was found in this model system that Myocd itself functions
in a cardiomyocyte autonomous manner to regulate myocyte
gene expression andmyofibrillar organization and to prevent
cardiomyocyte apoptosis in response to physiological hemo-
dynamic stress [43].
In light of these results, it is not surprising that
MYOCD has previously been implicated in remodeling
of ventricular myocardium in response to either physio-
logical or pathological pressure-overload hypertrophy [56–
58]. In addition, MYOCD is necessary for and mediates
the hypertrophic response of ventricular myocardium to a
variety of stimuli such as phenylephrine, endothelin, isopro-
terenol, aldosterone, angiotensin II, insulin and insulin-like
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Table 1: Mouse loss-of-function studies of Myocd-related family.
Gene knockout Embryonic cardiovascular phenotype Embryonic phenotype After-birth phenotype Reference
Myocd Constitutive
Block in SMC diﬀerentiation; heart
development is obviously normal
Lethal;
early-to-mid-gestation
No survivors [42]
Myocd
Conditional,
heart
restricted
Obviously normal heart development Obviously normal DCM, HF [43]
Mrtf-A Constitutive No obvious abnormalities Obviously normal
Myoepithelial defects
of the mammary gland;
[44]
poor hypertrophic
response
[45]
Mrtf-A Constitutive
65%-no obvious abnormalities; 65%-obviously normal
Myoepithelial defects
of the mammary gland35%-dilated heart
35%-lethal,
early-to-mid-gestation
[46]
Mrtf-B Constitutive
Double outlet RV, ventricular septal defects,
thin-walled myocardium, abnormal
patterning of the branchial arch arteries
Lethal; midgestation No survivors [47]
Mrtf-B Constitutive
Double outlet RV, cardiac outflow tract
defects, ventricular septal defects, persistent
truncus arteriosus
Lethal, late gestation No survivors [48]
Mrtf-B Constitutive
Ventricular septal defects, thin myocardium,
truncus arteriosus
Lethal; late gestation
Only a few grossly
normal survivors
[49]
RV: right ventricle; HF: heart failure; DCM: dilated cardiomyopathy.
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Figure 2: Dissecting the cell-autonomous roles of myocardin and MRTF-A in adult ventricular myocardium. Red arrows indicate up-
or downregulation. In cardiomyocytes, forced expression of either Myocd or Mrtf-A induces hypertrophic gene expression and myocyte
enlargement, whereas inhibition of any of these factors markedly attenuates hypertrophic responses. Although both factors display
prohypertrophic activities, MYOCD, but not MRTF-A, is absolutely required for myocyte structural integrity and survival [43]. In cardiac
fibroblasts, forced expression of Mrtf-A activates profibrosis gene expression and myofibroblast diﬀerentiation, whereas a loss of functional
Mrtf-A leads to opposite eﬀects. Forced Myocd expression stimulates both SM (including markers of myofibroblast diﬀerentiation) and
cardiac genes (including cardiac ion channels and connexins) in ventricular fibroblasts.
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growth factors, and beta-transforming growth factor (TGF-
β). Forced expression of Myocd in cultured cardiomyocytes
increases cell size and expression of molecular markers
of cardiac hypertrophy, whereas knockdown of Myocd
attenuates hypertrophic response capacity of cardiomyocytes
[58–63]. Hypoxia in neonatal cardiomyocytes increases levels
of MYOCD and ROS (reactive oxygen species) resulting
in cellular hypertrophy, which can be partly reversed by
atorvastatin treatment [64]. Collectively, the experimental
data indicate at least two important roles for MYOCD in
adult cardiomyocytes: its role in maintenance of structural
integrity and survival of cardiomyocytes and its role as a
prohypertrophic factor in hypertrophic remodeling induced
by genetic models, aortic constriction, and neurohumoral
factors.
Despite the popular assumption that MYOCD is ex-
pressed almost exclusively in cardiac and SM cells, MYOCD
expression was also detected in human fibroblasts [65] where
it is involved in functional diﬀerentiation and has a negative
role in cell proliferation [66]. In fact, in model cell-based
assays overexpression of Myocd resulted in inhibition of
cell-cycle progression at the G2/M phase and formation
of polyploidy cells [67]. MRTF-A and MRTF-B also exert
antiproliferative eﬀects on fibroblasts [68].
Expression of Myocd in mouse cardiac fibroblasts has
not been detected [69] but rat cardiac fibroblasts cultured in
a medium conditioned by mesenchymal stem cells (MSCs)
did express Myocd [70]. In rat cardiac fibroblasts, Myocd
expression appears to be age dependent and influenced by
hypoxia-inducible factor 1α [71].
It has been demonstrated that MYOCD-mediated trans-
activation of target genes is promoter and cell context
dependent [72, 73]. MYOCD alone was not suﬃcient
to activate cardiac-specific genes in pluripotent 10T1/2
fibroblasts [74, 75]. Ectopic Myocd expression in skeletal
muscle-like BC3H1 cell line induced cardiac and SM genes
and stimulated formation of SM-like filaments with no
evidence for cardiac sarcomerogenesis [76]. Infection of
human epicardial cells with an adenovirus vector encoding
Myocd co-activated both SM and cardiac marker genes
but did not lead to the assembly of SM-like filaments
[77]. Similarly, forced Myocd expression resulted in the
activation of a broad range of cardiomyocyte and SM
genes in both human foreskin-derived [65] and myocardial
scar (MSFs) fibroblasts [78]. Although such MYOCD-forced
MSFs did not acquire the cardiomyocyte structural and
functional phenotype, they became capable of conducting an
electrical impulse. In vitro, placing of Myocd-forced fibrob-
lasts between two separate cardiomyocyte fields resulted
in resynchronization of two dyssynchronously beating car-
diomyocyte areas [78]. Of note, forced expression of Myocd
enhances the therapeutic eﬀect of MSCs implanted into the
infracted area of postmyocardial infarction (MI) in mice
[79].
Myocd expression is upregulated by TGF-β1 in both
fibroblasts [66] and SM cells [80], and MYOCD participates
in TGF-β1 signal-transducing pathways to activate SM
gene transcription [81, 82]. Cardiac TGF-β1 expression is
upregulated in both animal models of MI and ventricular
hypertrophy and patients with hypertrophic or DCM [83].
Although unproven as yet, it is tempting to speculate that in
the infarcted heart TGF-β1 induction of Myocd expression
might contribute to fibroblast-to-myofibroblast transition.
In this sense, a very recent report provides direct evidence
that both MRTF-A and MRTF-B are key regulators of TGF-
β1-induced fibroblast-to-myofibroblast transition [84].
4.2. MRTF-A. Consistent with its discovery as a MYOCD-
related factor, it has initially been suggested that MRTF-A
plays a potentially important role in the heart [31]. However,
evidence of this has been found only recently with the use
of cardiac dysfunction models in adult Mrtf-A null mice. It
is appropriate to keep in mind that under basal conditions
Mrtf-A null mice did not manifest any obvious cardiac
structural or physiological deficiencies [44], and inactivation
of Mrtf-A expression was not associated with changes in
Myocd or Mrtf-B expression in mutant hearts [45].
In vivo studies, using the aortic banding model, indicated
that loss of Mrtf-A inhibits or diminishes activation of
the hypertrophic gene program induced in left ventricular
(LV) myocardium by mechanical pressure overload. At
the morphological level, a degree of LV hypertrophy was
also decreased in Mrtf-A mutant mice with experimentally
induced chronic pressure overload as compared to controls.
The same eﬀects were also observed in Mrtf-A-null mice
subjected to chronic angiotensin II treatment [45]. Taken
together, the results identified MRTF-A as a factor mediating
prohypertrophic signaling evoked by both mechanical stress
and neurohumoral stimulation in ventricular myocardium.
However, it remained uncertain if MRTF-A itself func-
tions in a cardiomyocyte autonomous manner to regulate
ventricular hypertrophy. Recent experiments using cultured
neonatal cardiomyocytes have demonstrated that overex-
pression of Mrtf-A does induce hypertrophic growth and
expression of cardiac hypertrophy marker genes in these
cells. In addition, it was found that the expression of
both Mrtf-A and Myocd is induced by hypertrophic signals,
whereas dominant-negative mutants of these factors (lack-
ing TAD domain, see Figure 1) attenuate agonist-induced
cardiomyocyte hypertrophy. Also, inhibition of endogenous
Mrtf-A expression reduced phenylephrine, angiotensin-II,
and TGF-β-induced hypertrophy in neonatal cardiomy-
ocytes [63]. These data, together with those of Mrtf-A
null mice [45, 51], indicate that besides MYOCD, MRTF-
A can play an important role in cardiac hypertrophy as a
myocardial prohypertrophic factor.
In the adult heart,Mrtf-A is robustly expressed in normal
cardiac fibroblasts which are activated to become SM-like
myofibroblasts in response to MI. Myofibroblasts strongly
express α-SM actin and extracellular matrix (ECM) proteins.
In the recent report [69], MIs were generated using Mrtf-
A null and wide-type adult mice by surgical ligation of the
left anterior descending coronary artery. Both, a significantly
reduced infarct size and attenuated upregulation of the
ECM markers (collagens, elastin) in the border zone, were
observed in MIMrtf-A null compared to MI wide-type mice.
The fibroblast-to-myofibroblast transition is believed to be
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primarily responsible for fibrotic remodeling of the post-
MI heart. The expression of SM markers of myofibroblast
activation, as well as a density of myofibroblasts in the MI
border zone, was attenuated in Mrtf-A-null mice.
Also, Mrtf-A null mice display reduced myocardial fibro-
sis in response to angiotensin treatment. Forced expression of
Mrtf-A in isolated cardiac fibroblasts was suﬃcient to activate
myofibroblast-associated SM genes that were downregulated
in MI Mrtf-A null hearts [69]. These results suggest that
MRTF-A can play an essential role in promoting fibroblast-
to-myofibroblast transition and fibrotic remodeling in the
post-MI heart. (For more detailed comments and nuances
related to MRTF-A-regulated pathways of myofibroblast
activation, see [85]).
5. Myocardin Family Proteins and Heart Disease
As mentioned above, many lines of evidence have implicated
MYOCD as an important regulator of hypertrophic growth
of the heart. However, it was not until recently that the
ability of MYOCD to promote cardiac hypertrophy in vivo
was directly examined. In neonatal piglets, in vivo forced
expression of MYOCD in ventricular myocardium resulted
in activation of a set of fetal cardiac and SM genes associated
with impaired systolic performance although no significant
change in heart-to-body weight ratio was detected in
MYOCD-transfected compared with control-sham animals
[86]. In neonatal piglets, the right (RV) and left (LV)
ventricles display such a diﬀerent degree of hypertrophy that
the RV can be used as a slower heart-matched reference-
control for the much more rapidly thickening LV [87, 88].
Nevertheless, expression of MYOCD was found to be similar
in both the LV and RV of porcine as well as human
neonates [56]. The simplest interpretation of these data
is that although MYOCD does upregulate the expression
of a set of SRF/MYOCD-dependent genes in response to
hypertrophy signals, it alone is not suﬃcient to discriminate
among diﬀerent patterns of LV/RV remodeling in the adult
heart in vivo.
In addition to its role in adaptive gene expression
and maintenance of cardiac function, MYOCD has also
been implicated in the response of the adult heart to
pathological stresses during severe hypertrophic remodeling
[58, 89] and at end-stage HF due to dilated, ischemic,
and cardiotoxic CM [56, 58, 90]. All of these conditions
are characterized by upregulation of MYOCD expression in
failing LV myocardium. In addition, MYOCD SM targets
are also upregulated in failing myocardium in both animal
models and patients [91]. Although this correlative evidence
links MYOCD signaling to the acquisition of pathological
conditions, the role that MYOCD gene activation plays
in HF conditions in vivo has remained unclear. Recently,
we attempted to integrate upregulated MYOCD signaling
into the pathogenesis of HF, using targeted RNAi-mediated
MYOCD gene inhibition in the porcine model of dias-
tolic HF (DHF). In vivo silencing of endogenous MYOCD
at mid-advanced stages of DHF resulted in downregula-
tion of MYOCD-dependent SM-gene expression in failing
myocardium [92]. Such adjusting of MYOCD and SM-target
expression levels to the range of physiological variation
resulted in restoring diastolic function and extending the
survival of failing animals without compromising the physi-
ological functions of MYOCD signaling [43] as a part of the
adaptive response of the heart to stress.
To the best of our knowledge, the role of MRTF-A and
MRTF-B in failing myocardium was not evaluated in either
study. Nevertheless, the data from experiments with Mrtf-
A null mice strongly suggest that modulation of Mrtf-A
expression in hypertrophy-induced [45] or post-MI [69]
failing myocardium could be promising from therapeutic
point of view. Of note, mRNA splicing of the MRTF-B
gene was altered in myocardial samples from patients with
ischemic cardiomyopathy undergoing heart transplantation
[93].
6. Conclusion and Expectations
Currently, a majority of the gene therapy assays are con-
ducted using a single-candidate gene approach. There are
two main strategies applied to the search for target genes
for the treatment of HF. One is identification of terminal
eﬀector genes involved in the advanced and end-stage HF
in patients. Another is to establish a new target for HF,
searching for members of gene regulatory circuits, each
of which can play a role in the control of a branch of
terminal eﬀector genes in the network, in both normal and
diseased heart. Given the plethora of genes regulated by
partnership of SRF and members of the MYOCD family in
muscle cells, this balanced regulatory network plays a central
role in normal heart development and adult heart function,
whereas dysregulation of SRF/MYOCD/MRTF-dependent
gene expression contributes to numerous disease models of
the cardiovascular system.
Experimental manipulation of expression of MYOCD
family genes has allowed the development of new animal
models to study themechanisms of DCM (MYOCD), cardiac
hypertrophy, post-MI fibrosis (MRTF-A), and congenital
heart disease (MRTF-B). Knowledge gained from these
studies will guide the development of novel therapies for
the treatment and prevention of HF development. Mice with
a cardiomyocyte-specific deficiency in Myocd could aid in
the development of apoptosis-blocking therapies for HF.
Mrtf-A null models indicate that Mrtf-A inhibition might
be therapeutically beneficial in post-MI cardiomyopathy
settings. A normalization of activated MYOCD signaling in
ventricularmyocardium atmidstages of HF development can
improve impaired ventricular function.
Several cardiovascular-enriched microRNAs (miRNAs),
both downstream and upstream to Myocd, were found to be
involved in the SRF/MYOCD regulatory network [94–98].
In this sense, we suggest a promising therapeutic role for
miRNA mimics/inhibitors to modify exaggerated MYOCD
signaling in HF settings. In fact, recent data revealed that
miR-9 can suppress Myocd translational activity in vitro and
administration of the miR-9 mimic can attenuate cardiac
hypertrophy remodeling in vivo [97].
8 Biochemistry Research International
Finally, an understanding of synergistic or additive
interactions between MYOCD family factors in principal cell
types of myocardium (myocytes and fibroblasts) is crucial
before any therapeutic intervention could be entertained in
preclinical trials.
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